Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JKA97 is a novel synthetic benzylidene analog of harmine (a beta-carboline alkaloid) that exhibits potent anti-cancer activity. It has been shown to inhibit the growth and proliferation of various cancer cell lines, including breast, colon, and liver cancers, both in vitro and in vivo. Mechanistically, JKA97 induces G1 cell cycle arrest and apoptosis. It up-regulates the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) and p27 at the transcriptional level in a p53-independent manner, while down-regulating cyclin D1 and cyclin E. Additionally, JKA97-induced apoptosis is associated with Bax translocation and activation of the mitochondrial apoptotic pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JKA97.